Literature DB >> 31822994

[NMDAR autoantibodies as biomarker for fatigue in SLE].

M A Schramm, N Venhoff1.   

Abstract

Entities:  

Year:  2020        PMID： 31822994     DOI： 10.1007/s00393-019-00739-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  6 in total

1.  Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome.

Authors:  Maria B Lauvsnes; Mona K Beyer; Jan Terje Kvaløy; Ole J Greve; Simone Appenzeller; Ingeborg Kvivik; Erna Harboe; Anne B Tjensvoll; Lasse G Gøransson; Roald Omdal
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 2.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

3.  Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Hirotaka Kaneko; Katsuji Nishimura; Masanori Hanaoka; Sayuri Kataoka; Yuko Okamoto; Yasuhiro Katsumata; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2011-01-05       Impact factor: 7.580

4.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.

Authors:  L A DeGiorgio; K N Konstantinov; S C Lee; J A Hardin; B T Volpe; B Diamond
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

Review 5.  Clinical utility of circulating anti-N-methyl-d-aspartate receptor subunits NR2A/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus and Sjögren's syndrome: An updated meta-analysis.

Authors:  Sen Hee Tay; Anna-Marie Fairhurst; Anselm Mak
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

6.  Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.

Authors:  Vibeke Strand; Roger A Levy; Ricard Cervera; Michelle A Petri; Helen Birch; William W Freimuth; Z John Zhong; Ann E Clarke
Journal:  Ann Rheum Dis       Date:  2013-03-22       Impact factor: 19.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.